Med-IQ
Fabry Disease: When to Treat
E-Publication E-Publication

Fabry Disease: When to Treat


Time to Complete:
45 minutes
Released:
12/22/16
Expires:
12/21/17

Maximum Credits:

0.75 AMA PRA Category 1 Credit(s)

E-Publication E-Publication
Time to Complete:
45 minutes

Released:
12/22/16

Expires:
12/21/17

Maximum Credits:
0.75 AMA PRA Category 1 Credit(s)
Share on:
E-Publication E-Publication

Share on:


Time to Complete:
45 minutes
Released:
12/22/16
Expires:
12/21/17


Maximum Credits:
0.75 AMA PRA Category 1 Credit(s)


Overview: This 45-minute, CME-certified digital publication discusses the variability of Fabry disease (FD) manifestations. In addition, it presents management approaches for patients with FD, including disease monitoring and comprehensive therapy.

Faculty

William R. Wilcox, MD, PhD

Professor of Human Genetics and Pediatrics

Department of Human Genetics

Emory University School of Medicine

Atlanta, GA


Disclosure Policy

Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.


Disclosure Statement

The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.  

William R. Wilcox, MD, PhD
Consulting fees/advisory boards: Sanofi Genzyme
Contracted research: Amgen, Amicus Therapeutics, ArmaGen, BioMarin, F. Hoffmann-La Roche Ltd., Protalix Biotherapeutics, Sanofi Genzyme, Shire
 
The writer, peer reviewers, and activity planners have no financial relationships to disclose.


This activity has been approved for AMA PRA Category 1 Credit™.


This activity is supported by an educational grant from Sanofi Genzyme.

Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

Need help? If you need to speak with a member of our team, please call (toll-free) 866 858 7434 or email info@med-iq.com. For technical assistance, please refer to our support manual.